Office of Audit Services Opioid Reviews
The Office of Audit Services (OAS) is conducting a series of reviews related to the opioid epidemic. The map below combines these series of reviews, click on a state to learn about OAS's reviews completed in the state. For more information, use the dropdown box to select a specific series of OAS reviews related to the opioid epidemic.
Choose from the options below to view the maps.
Office of Audit Services Opioid Reviews
Use the map below to learn about opioid-related reviews being conducted throughout the country.
View this series in a text-based format.
States' Oversight of Opioid Prescribing and Monitoring of Opioid Use
Update on Oversight of Opioid Prescribing and Monitoring of Opioid Use: States Have Taken Action To Address the Opioid Epidemic
(A-09-20-01000)Translation
In this series of reviews, OIG reviewed the oversight of opioid prescribing and the monitoring of opioid use in selected States. Specifically, OIG reviewed the States' policies and procedures, data analytics, programs, outreach, and other efforts. To support HHS's ongoing efforts to identify and disseminate effective practices to address the opioid epidemic in the United States, these State-wide efforts are highlighted through a factsheet and a one-page highlights document for each of the selected States. The information from these reviews will be summarized in a report to the Centers for Medicare & Medicaid Services.
View this series in a text-based format.
Prevention of Prescription Opioid Drug Abuse and Misuse—Prescription Drug Monitoring Programs
In this series of reviews, OIG reviewed actions that selected States have taken, using Federal funds for enhancing prescription drug monitoring programs (PDMPs), to achieve program goals toward improving safe prescribing practices and preventing prescription drug abuse and misuse. OIG also determined whether the States complied with certain Federal requirements. This series includes States that have had a high number of overdose deaths, have had a significant increase in the rate of drug overdose deaths, or have received HHS funding to enhance their PDMPs.
View this series in a text-based format.
Medicaid Claims for Opioid Treatment Program Services
In this series of audits, OIG reviewed Medicaid payments for Opioid Treatment Program (OTP) services. Medicaid is a significant source of coverage and funding for behavioral health treatment services, including treatment of substance use disorder. OIG will determine whether selected State agencies complied with certain Federal and State requirements when claiming Medicaid reimbursement for OTP services.
View this series in a text-based format.
State and Tribal Opioid Response Grants Audit
In this series of audits, OIG reviewed Substance Abuse and Mental Health Services Administration (SAMHSA) grants to address the opioid overdose crisis. Specifically, these grants include State Targeted Response to the Opioid Crisis (Opioid STR), State Opioid Response (SOR), and Tribal Opioid Response (TOR) grants. OIG will determine how select States or Tribal agencies implemented programs under these grants and whether the activities of these agencies and subrecipients responsible for implementing the programs complied with Federal regulations and met program goals.
View this series in a text-based format.
Projects for Assistance in Transition from Homelessness Program
In this series of audits, OIG reviewed the Projects for Assistance in Transition from Homelessness (PATH) program. The Substance Abuse and Mental Health Services Administration (SAMHSA) awards grant funds to various States to operate the PATH program. The PATH program supports the delivery of outreach and various services to individuals with serious mental illness and those with co-occurring substance use disorders who are experiencing homelessness or are at imminent risk of becoming homeless. We will determine whether some of these grant recipients complied with Federal requirements in providing PATH program services.
View this series in a text-based format.
Last Updated April 26, 2024